HPV vaccination: the beginning of the end of cervical cancer? - A Review

Lepique, Ana Paula; Rabachini, Tatiana; Villa, Luisa L.

doi:10.1590/s0074-02762009000100001

Cited by 22 publications

(21 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, we investigated two populations of females, who attended either a private or a public gynaecological service, from the state Rio de Janeiro. Prophylactic vaccines for HPV infection are now a reality, but since geographical variations in the prevalence of HPV types and co-factors have been documented worldwide (Lepique et al 2009), further knowledge of the epidemiological data regarding HPV infection in our country may assist health authorities in planning local prophylactic and therapeutic strategies of cancer control.…”

mentioning

confidence: 99%

Risk factors associated with human papillomavirus infection in two populations from Rio de Janeiro, Brazil

Silva

Rosa

Moyse

et al. 2009

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Risk factors associated with human papillomavirus infection in two populations from Rio de Janeiro, Brazil

Silva

Rosa

Moyse

et al. 2009

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…After four vaccinations, neither adverse side effects nor clinical responses were observed in patients [126]. Phase I/II trials have also tested two HPV-16 peptides, E7 [11][12][13][14][15][16][17][18][19][20] and E7 [86][87][88][89][90][91][92][93] , and a PADRE emulsion in the Montanide ISA 51 adjuvant in patients with recurrent or refractory cervical cancer [105,106]. This therapeutic vaccine showed no significant adverse effects in both trials.…”

Section: Human Trials Of Immunotherapy For Hpv Infectionmentioning

confidence: 99%

“…The time between virus infection and tumor development is typically 10-20 years, so a large proportion of the global population is already infected and cannot be treated by the prophylactic vaccine [11,12,15,16]. To combat established infections, it is necessary to develop a therapeutic vaccine against high-risk HPV, particularly HPV-16 and HPV-18 strains [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

Liu¹,

Hussein²,

Tóth³

et al. 2012

CTMC

View full text Add to dashboard Cite

Cervical cancer is the second leading cause of cancer in women worldwide. Human papillomavirus (HPV) is responsible for all cases of cervical cancer. Commercial prophylactic HPV vaccines are now available, but unfortunately these vaccines have no therapeutic effect against established HPV infections. In order to accelerate the control of cervical cancer and treat established HPV infections, it is necessary to develop therapeutic vaccines to eradicate HPV by generating cell-mediated immunity against HPV infected cells. Two HPV-encoded early proteins, the E6 and E7 oncoproteins, are the preferred targets because they are consistently expressed in virtually all cervical cancer cells and are necessary for the induction and maintenance of HPV-associated disease. A variety of vaccine strategies have been employed targeting immune responses to these proteins. Peptide-based vaccines are a promising strategy for the development of therapeutic HPV vaccines because of their safety, stability, and ease of production. This review summarizes the prospects of peptidebased vaccines for the treatment of established HPV infections. We address the challenges that scientists currently face for developing peptide-based vaccines and explore feasible strategies for improving the potency of the induced immune response with the aim of treating established HPV infections.

show abstract

“…Atualmente, existem duas vacinas profiláticas contra o HPV comercializadas. Elas previnem muitas infecções pelo vírus, reduzindo assim o risco de doenças associadas ao HPV (LEPIQUE; RABACHINI; VILLA, 2009;JOSÉ, 2008).…”

Section: Vacinas Profiláticas Contra a Infecção Por Hpvunclassified

Aspectos imunológicos da infecção pelo vírus do papiloma humano (HPV)

Limberger

Oliveira

Corrêa

et al. 2012

Semin. Cienc. Biol. Saude

View full text Add to dashboard Cite

O vírus do papiloma humano (HPV-human papiloma virus) pode infectar até 80% das pessoas, principalmente as sexualmente ativas. O risco e a sintomatologia da infecção são distintos entre os gêneros. Sabe-se que existem mais de 150 sorotipos e estes são agrupados por seu tropismo. Embora a maioria das infecções siga um curso benigno, a infecção persistente por certos sorotipos pode levar ao desenvolvimento de câncer. Os sorotipos 16 e 18 estão envolvidos com uma forma grave de lesão, acarretando câncer, principalmente do colo do útero. Os sorotipos 6 e 11 são descritos como causadores de verrugas anogenitais. O vírus, de aproximadamente 8.000 pb, se instala na célula e por meio da expressão das oncoproteínas E6 e E7, levando à inibição de proteínas como a p53 e a pRB, importantes na apoptose e na parada do ciclo celular. As vacinas atuais geram imunidade contra os sorotipos 6, 11, 16 e 18. A vacina pode ser tetravalente (quatro sorotipos: 6, 11, 16 e 18) ou bivalente (16 e 18). Ambas apresentam proteção cruzada contra a infecção por sorotipos não inclusos nas vacinas, porém não possuem caráter terapêutico. O presente trabalho teve como proposta revisar os avanços sobre a infecção pelo HPV, os aspectos imunológicos e as vacinas profiláticas disponíveis. Palavras -Chaves: HPV. Vírus do papiloma humano. Vacinas. Mecanismos imunológicos. Câncer de colo de útero.

show abstract

HPV vaccination: the beginning of the end of cervical cancer? - A Review

Cited by 22 publications

References 83 publications

Risk factors associated with human papillomavirus infection in two populations from Rio de Janeiro, Brazil

Risk factors associated with human papillomavirus infection in two populations from Rio de Janeiro, Brazil

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

Aspectos imunológicos da infecção pelo vírus do papiloma humano (HPV)

Contact Info

Product

Resources

About